Organization
Department of Radiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
1 abstract
Abstract
Final survival outcomes and exploratory biomarker analysis from the randomized, phase 2 neoSCORE trial: Two versus three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small cell lung cancer.Org: The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, Department of Thoracic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China, Department of Pathology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China,